全球领先的新经济产业第三方数据挖掘与分析机构
关于“疫苗”的报告
-
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破，中国生物医药产业快速发展，2018年，单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元，实现同比增长。iiMedia Research(艾媒咨询)监测发现，生物医药产业网络言值指数为49.7，网民评价态度偏向正面，上海网民对生物医药产业的关注度最高。未来，随着中国生物医药行业上市公司数量增多，行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry. -
艾媒咨询 | 2025年中国病毒防治产业发展状况及重点企业大数据监测报告
当前，全球病毒变异迭代加速，公共卫生防控常态化需求持续凸显，叠加中国生物医药技术创新升级与政策精准赋能，病毒防治产业正迎来新一轮发展机遇与调整周期。全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国病毒防治产业发展状况及重点企业大数据监测报告》显示，2025年病毒防治产业集中度持续提升，营收前三名企业合计贡献TOP10整体营收的42.13%，研发投入累计投入达16.59亿元，头部引领效应凸显。细分领域中，以岭药业依托中药防治优势实现扭亏为盈，前三季度归母净利润实现10亿元，毛利率维持60%以上；华大基因深耕精准医学检测细分领域，前三季度营收规模超25亿元，市净率达2.29倍，展现出细分赛道的发展韧性。艾媒咨询分析师认为，2025年病毒防治产业处于调整转型期，研发创新、产品迭代及市场布局优化成为企业突破发展瓶颈、提升核心竞争力的关键，同时也将逐步筑牢公共卫生安全保障的产业根基，推动构建人类卫生健康共同体。
At present, the global iteration of virus variants is accelerating, and the demand for the normalization of public health prevention and control remains prominent. Coupled with the innovation and upgrading of China's biopharmaceutical technology and precise policy support, the virus prevention and control industry is ushering in a new round of development opportunities and adjustment cycle. According to the 2025 Report on the Development Status of China's Virus Prevention and Control Industry and Big Data Monitoring of Key Enterprises newly released by iiMedia Research, a world-leading third-party institution for data mining and analysis of the new economy industry, the concentration of the virus prevention and control industry continued to rise in 2025. The top three enterprises in terms of revenue contributed 42.13% of the total revenue of the top 10 enterprises combined, with a cumulative R&D investment of 1.659 billion yuan, highlighting the leading effect of head enterprises.
In the segmented sectors, Yiling Pharmaceutical turned losses into profits by virtue of its advantages in traditional Chinese medicine (TCM) prevention and control, achieving a net profit attributable to shareholders of listed companies of 1 billion yuan in the first three quarters with a gross profit margin maintained above 60%. BGI Genomics has deepened its layout in the segmented field of precision medical testing, recording a revenue scale of over 2.5 billion yuan in the first three quarters and a price-to-book ratio of 2.29 times, demonstrating the development resilience of the segmented track.
Analysts from iiMedia Research hold that the virus prevention and control industry is in a period of adjustment and transformation in 2025. R&D innovation, product iteration and optimization of market layout have become the key for enterprises to break through development bottlenecks and enhance core competitiveness. Meanwhile, this will gradually consolidate the industrial foundation for public health security and boost the building of a global community of health for all. -
艾媒报告|2020年1-2月中国母婴行业运行状况及企业商情动态月度报告
本报告研究涉及企业/品牌/案例：爹地宝贝，帮宝适，巴拉巴拉；其他提及企业/品牌：掌通家园，智慧树，宝宝巴士，小伴龙，妈妈网孕育，宝宝树孕育，柚宝宝孕育，亲宝宝，妈妈网轻聊，小豆苗疫苗助手，宝宝知道，辣妈帮，妈妈帮，孕期伴侣
2020年1-2月中国母婴产品线上交易较往年增多。艾媒咨询分析师认为，疫情出门受限期间，手机App成为了丰富用户业余生活的重要工具，母婴垂直线类平台或获得发展机遇，迎来上升期。
During the epidemic, the top three most downloaded APP types among mother groups were news, maternal and child vertical, and social. In January 2020, the mother-and-baby app with the largest monthly active population was conceived by Maoma.com, with a total of 17,514,400 people, an increase of 2.47% from the previous month. -
艾媒咨询｜2021-2022年中国母婴行业新媒体营销价值研究报告
本报告涉及的案例/品牌/企业：妈妈网
iiMedia Research（艾媒咨询）数据显示，2021年中国母婴市场规模将超过48000亿元，预计2024年将超过76000亿元。随着母婴群体消费意识逐渐前置，早阶母婴消费市场潜力不断被开发，并且母婴商品的选购差异化逐渐凸显，母婴产品分阶段购买成为新消费趋势。头部母垂平台凭借庞大的用户规模以及较高的品牌影响力，实现分阶段的精准信息传递，充分享受品牌带来的市场红利，实现获得更大的母婴市场份额。
According to the data of iiMedia Research, the scale of China's maternal and infant market will exceed 4800 billion yuan in 2021 and is expected to exceed 7600 billion yuan in 2024. With the gradual advance of the consumption awareness of mother and baby groups, the market potential of early-stage mother and baby consumption has been continuously developed, and the purchase differentiation of mother and baby goods has gradually become prominent. The phased purchase of mother and baby products has become a new consumption trend. With its huge user scale and high brand influence, the head mother hanging platform realizes accurate information transmission in stages, fully enjoys the market dividends brought by the brand, and achieves greater market share of mothers and infants.
